ID KHYG-1 AC CVCL_2976 SY KHYG1; KHYG DR EFO; EFO_0022649 DR ArrayExpress; E-MTAB-7721 DR ArrayExpress; E-MTAB-7722 DR cancercelllines; CVCL_2976 DR Cell_Model_Passport; SIDM01661 DR Cosmic; 1534877 DR Cosmic; 1542070 DR Cosmic; 2025323 DR Cosmic; 2390214 DR Cosmic; 2785203 DR DepMap; ACH-001100 DR DSMZ; ACC-725 DR DSMZCellDive; ACC-725 DR FANTOM5_SSTAR; 10777-110G3 DR GEO; GSM472000 DR IARC_TP53; 13193 DR JCRB; JCRB0156 DR JCRB; NIHS0226 DR Lonza; 733 DR Wikidata; Q54899912 RX DOI=10.1016/B978-0-12-221970-2.50457-5; RX PubMed=10803505; RX PubMed=10803526; RX PubMed=16827800; RX PubMed=19194464; RX PubMed=21052088; RX PubMed=25586472; RX PubMed=31160637; WW Info; Wikipedia; -; https://en.wikipedia.org/wiki/KHYG-1 CC Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). CC Part of: LL-100 blood cancer cell line panel. CC Population: Japanese. CC Characteristics: IL2 dependent. CC Doubling time: 24-48 hours (PubMed=10803526); ~30-40 hours (DSMZ=ACC-725); ~54 hours (Note=Lot 11012010), ~30 hours (Note=Lots 07242006 and 11202015), ~25 hours (Note=Lot 10182016) (JCRB=JCRB0156). CC HLA typing: A*11:01:01,24:02:01; B*35:01:01,54:01:01; C*01:02:01,03:03:01; DPA1*02:01:01,02:01:01; DPB1*19:01,14:01:01; DQA1*01:03:01,01:03:01; DRA*01:01:01,01:02:02; DRB1*08:03:02,11:01:01 (DSMZCellDive=ACC-725). CC Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (DepMap=ACH-001100). CC Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=10803526; DepMap=ACH-001100). CC Omics: Genomics; Whole exome sequencing. CC Omics: Transcriptomics; Microarray. CC Omics: Transcriptomics; RNAseq. CC Discontinued: JCRB; NIHS0226; true. CC Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178. ST Source(s): DSMZ=ACC-725; JCRB=JCRB0156 ST Amelogenin: X ST CSF1PO: 12 ST D13S317: 9,13 ST D16S539: 9 ST D18S51: 13,18 ST D19S433: 13,14 ST D21S11: 30,32.2 ST D2S1338: 17,19 ST D3S1358: 15,16 ST D5S818: 9,11 ST D7S820: 10,11 ST D8S1179: 13 ST FGA: 21,24 ST Penta D: 11,13 ST Penta E: 5 ST TH01: 6 ST TPOX: 9,11 ST vWA: 17 DI NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma OX NCBI_TaxID=9606; ! Homo sapiens (Human) SX Female AG 45Y CA Cancer cell line DT Created: 04-04-12; Last updated: 10-04-25; Version: 30 // RX PubMed=10803505; DOI=10.1038/sj.leu.2401778; RA Drexler, Hans Gunther RA Matsuo, Yoshinobu RT "Malignant hematopoietic cell lines: in vitro models for the study of RT natural killer cell leukemia-lymphoma."; RL Leukemia 14:777-782(2000). // RX PubMed=10803526; DOI=10.1038/sj.leu.2401769; RA Yagita, Masato RA Huang, Cheng-Long RA Umehara, Hisanori RA Matsuo, Yoshinobu RA Tabata, Rie RA Miyake, Masayuki RA Konaka, Yoshiteru RA Takatsuki, Kiyoshi RT "A novel natural killer cell line (KHYG-1) from a patient with RT aggressive natural killer cell leukemia carrying a p53 point RT mutation."; RL Leukemia 14:922-930(2000). // RX PubMed=21052088; DOI=10.1038/leu.2010.255; RA Iqbal, Javeed RA Weisenburger, Dennis D. RA Chowdhury, Aparajita RA Tsai, Ming-Ying RA Srivastava, Gopesh RA Greiner, Timothy Charles RA Kucuk, Can RA Deffenbacher, Karen E. RA Vose, Julie Marie RA Smith, Lynette RA Au, Wing Yan RA Nakamura, Shigeo RA Seto, Masao RA Delabie, Jan RA Berger, Francoise RA Loong, Florence RA Ko, Young-Hyeh RA Sng, Ivy RA Liu, Xin RA Loughran, Thomas P. Jr. RA Armitage, James Olen RA Chan, Wing-Chung RG International Peripheral T-cell Lymphoma Project; RT "Natural killer cell lymphoma shares strikingly similar molecular RT features with a group of non-hepatosplenic gammadelta T-cell lymphoma RT and is highly sensitive to a novel aurora kinase A inhibitor in RT vitro."; RL Leukemia 25:348-358(2011). // RX PubMed=16827800; DOI=10.1111/j.1349-7006.2006.00226.x; PMCID=PMC11159954; RA Liu, Angen RA Takakuwa, Tetsuya RA Luo, Wen-Juan RA Fujita, Shigeki RA Aozasa, Katsuyuki RT "Alterations in ATR in nasal NK/T-cell lymphoma and chronic active RT Epstein-Barr virus infection."; RL Cancer Sci. 97:605-610(2006). // RX DOI=10.1016/B978-0-12-221970-2.50457-5; RA Drexler, Hans Gunther RT "The leukemia-lymphoma cell line factsbook."; RL (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001). // RX PubMed=25586472; DOI=10.1038/ncomms7025; PMCID=PMC7743911; RA Kucuk, Can RA Jiang, Bei RA Hu, Xiao-Zhou RA Zhang, Wen-Yan RA Chan, John K.C. RA Xiao, Wen-Ming RA Lack, Nathan RA Alkan, Can RA Williams, John C. RA Avery, Kendra N. RA Kavak, Pynar RA Scuto, Anna RA Sen, Emel RA Gaulard, Philippe RA Staudt, Louis Michael RA Iqbal, Javeed RA Zhang, Wei-Wei RA Cornish, Adam RA Gong, Qiang RA Yang, Qun-Pei RA Sun, Hong RA d'Amore, Francesco Annibale RA Leppa, Sirpa RA Liu, Wei-Ping RA Fu, Kai RA de Leval, Laurence RA McKeithan, Timothy W. RA Chan, Wing-Chung RT "Activating mutations of STAT5B and STAT3 in lymphomas derived from RT gammadelta-T or NK cells."; RL Nat. Commun. 6:6025.1-6025.12(2015). // RX PubMed=31160637; DOI=10.1038/s41598-019-44491-x; PMCID=PMC6547646; RA Quentmeier, Hilmar RA Pommerenke, Claudia RA Dirks, Wilhelm Gerhard RA Eberth, Sonja RA Koeppel, Max RA MacLeod, Roderick A.F. RA Nagel, Stefan RA Steube, Klaus G. RA Uphoff, Cord C. RA Drexler, Hans Gunther RT "The LL-100 panel: 100 cell lines for blood cancer studies."; RL Sci. Rep. 9:8218.1-8218.14(2019). // RX PubMed=19194464; DOI=10.1038/leu.2009.3; RA Iqbal, Javeed RA Kucuk, Can RA Deleeuw, Ronald J. RA Srivastava, Gopesh RA Tam, Wayne RA Geng, Hui-Min RA Klinkebiel, David L. RA Christman, Judith K. RA Patel, Kavita N. RA Cao, Ka-Jia RA Shen, Li-Jun RA Dybkaer, Karen RA Tsui, Ivy F.L. RA Ali, Hesham H. RA Shimizu, Norio RA Au, Wing Yan RA Lam, Wan L. RA Chan, Wing-Chung RT "Genomic analyses reveal global functional alterations that promote RT tumor growth and novel tumor suppressor genes in natural killer-cell RT malignancies."; RL Leukemia 23:1139-1151(2009). //